Subscribe (free)
About NaturalNews
Contact Us
Write for NaturalNews
Media Info
Advertising Info

Alzheimer's drug clinical trial halted after nine deaths

Monday, May 10, 2010 by: David Gutierrez, staff writer
Tags: Alzheimer's, drug trials, health news

Most Viewed Articles
Popular on Facebook
(NaturalNews) Elan Corp. and Transition Pharmaceuticals have called a premature halt on trials on the two highest doses of their experimental Alzheimer's drug ELND005 after the deaths of nine study participants.

"Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses. A direct relationship between ELND005 and these deaths has not been established," the companies said.

The announcement was greeted as particularly bad news for Elan, which recently had to update the safety label of its multiple sclerosis drug Tysabri after studies showed a heightened risk of death among patients taking it.

Elan and Transition had already completed a successful Phase I trial of the new drug, which showed that it built up in high concentrations in the brain and appeared to preserve higher levels of a key nerve-protecting enzyme. In the Phase II trial, the companies had been testing 353 people with either 250 milligram, 1,000 milligram or 2,000 milligram doses of the drug.

The decision to halt the two higher-dose trials was made in consultation with the study's Independent Safety Monitoring Committee. As no deaths were seen in the 250 milligram group, those tests will continue.

Although there was little effect on the companies' stock prices, analysts predicted an uphill battle for approval of the experimental drug.

"This is a considerable blow for the progress of the drug," Ian Hunter of Goodbody said.

"At the very least, efficacy at the lower dose will need to be compelling to justify development and ultimate approval," said Jack Gorman of Davy Stockbrokers.

Elan is also developing another Alzheimer's drug, this one in partnership with Johnson & Johnson, but progress on that product is not nearly as advanced.

Alzheimer's disease is the most common form of dementia, affecting more than five million people in the United States alone. The disease is characterized by a progressive loss of cognitive function, and is currently incurable. An Alzheimer's drug has been called the "holy grail" for pharmaceutical companies, but so far no effective cures seem forthcoming.

Sources for this story include: www.reuters.com; www.irishtimes.com.
STAY INFORMED! Free subscription to the Health Ranger's email newsletter
Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.